|
| Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more |
Roche drinks in COVID test sale gains but preps for the well to run dry Trump era rule that expanded duration of short-term health plans in Democrats' crosshairs Is AstraZeneca finally ready to score with underachieving cancer drug tremelimumab? Another setback for Axsome as migraine med expected to get a no from FDA AI predicts lung cancer tumor growth after radiation: NHS study SAS Health partners with Microsoft for advanced health analytics with interoperable platform Weeks after Sanofi flop, Roche's rival breast cancer drug flunks phase 2 test Roche delays Polivy's blockbuster lymphoma filing as FDA asks for more data Labcorp beefs up at-home testing options with Getlabs’ on-demand blood draw service Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansion Here's why some systems say they're comfortable relaxing hospital mask requirements UPDATE: Nkarta touts a double dose of data for natural killer cell therapies Featured Story | By Conor Hale Omicron’s surge in January drove Roche’s diagnostics sales to new highs in the first quarter of this year, as high demand for rapid COVID-19 tests joined forces with the momentum in the division’s base businesses. read more |
| |
|---|
|
Top Stories By Robert King Democrats and advocacy groups are making a major push to get HHS to pull a Trump-era rule that expanded short-term health plans. read more By Kevin Dunleavy After years of floundering with promising cancer drug tremelimumab, AstraZeneca may finally bring it to the market in the United States. The company said that the FDA has accepted its BLA for priority review of treme as a single-dose primer added to its PD-L1 inhibitor Imfinzi for treating first-line unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer. read more By Max Bayer Axsome Therapeutics is bracing for another setback as the FDA is now expected to nix an application for its migraine med due to unresolved manufacturing issues. read more By Andrea Park The machine learning model was able to predict a patient’s two-year risk of recurrence more accurately than current methods, including a widely used staging system. read more By Rebecca Torrence Global analytics provider SAS Health is teaming up with Microsoft to use the tech giant's new health data services platform to increase the accessibility of advanced health analytics. read more By Nick Paul Taylor Chalk up another setback to the oral SERDs. In the wake of data that sank Radius Health's stock and the failure of Sanofi’s prospect, Roche has revealed giredestrant missed the mark in a midphase breast cancer trial, raising doubts about the drug ahead of further data drops. read more By Angus Liu Roche is banking on a possible billion-dollar expansion for Polivy in newly diagnosed lymphoma. But the company’s plan to disrupt 20 years of standard treatment is taking longer than expected. read more By Andrea Park Labcorp’s at-home testing services just got a little more, well, at-home. read more By Annalee Armstrong Arrowhead and Vivo Capital are forming a new company called Visirna Therapeutics to take four of the biotech’s RNAi therapies to China, with an initial investment of $60 million from the venture capital firm to get going. read more By Fraiser Kansteiner Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East Coast. read more By Dave Muoio Houston Methodist and UnityPoint Health are among those letting staff and visitors cut back on masking outside clinical areas. With constant surveillance, they say the policy offers much-needed relief to staff members grappling with pandemic burnout. read more By Gabrielle Masson Following a blockbuster IPO and partnership with CRISPR, clinical-stage biotech Nkarta has released some of the first data for its two leading engineered natural killer (NK) cell programs to treat cancer. read more | 